<DOC>
	<DOCNO>NCT02300142</DOCNO>
	<brief_summary>This voluntary study allow subject receive placebo GEN-003-002 randomized , blind manner , 1 6 active combination GEN-003 Matrix-M2 . Objectives : - To compare impact clinical Herpes Simplex Virus type-2 ( HSV-2 ) disease among 6 different combination GEN-003 antigen Matrix-M2 adjuvant measure : - Time first clinical and/or virologic recurrence Dose 3 ( Day 43 ) - Proportion subject recurrence free 6 12 month last dose vaccine - Lesion rate ( percent day genital lesion present ) post-vaccination follow-up period - Antiviral use . - To evaluate safety tolerability GEN-003 combination Matrix-M2 .</brief_summary>
	<brief_title>Rollover Trial Placebo Subjects Previously Enrolled Into GEN-003-002 Study</brief_title>
	<detailed_description />
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Herpes Genitalis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Subjects receive placebo GEN003002 complete study Day 71 per protocol , include collection least 45 anogenital swabs Days 43 71 . 2 . Enrolled trial within 56 day complete Day 71 GEN003002 . 3 . Willing able provide write informed consent . 4 . Willing perform comply study procedure include attend clinic visit schedule . 5 . Men woman childbearing potential , must willing practice highly effective method contraception may include , limited , abstinence , monogamous relationship vasectomize partner , vasectomy , license hormonal method , intrauterine device ( IUD ) , barrier method ( e.g. , condom , diaphragm ) 28 day 90 day receive Study Drug . 1 . On suppressive antiviral medication within 7 day prior first dose Study Drug . 2 . Collection le 45 anogenital swabs Days 43 71 GEN003002 study . 3 . History form ocular Herpes Simplex Virus ( HSV ) infection , HSVrelated erythema multiforme , herpes meningitis encephalitis . 4 . Immunocompromised individual , include receive immunosuppressive dos corticosteroid ( 20 mg prednisone give daily alternative day 2 week within 6 month prior first dose Study Drug , dose corticosteroid within 30 day first dose Study Drug , high dose inhale corticosteroid [ &gt; 960 μg/day beclomethasone dipropionate equivalent ] ) immunosuppressive agent . 5 . Presence history autoimmune disease , regardless current treatment . 6 . Positive serologic test Human Immunodeficiency Virus ( HIV1 ) hepatitis C infection ( absence negative PCR result ) ; positive hepatitis B surface antigen ( HBsAg ) within 6 month prior first dose Study Drug . 7 . Clinically significant laboratory abnormality value ≥ Grade 2 within 56 day prior first dose Study Drug . 8 . Receipt blood product within 90 day prior first dose Study Drug . 9 . Receipt live vaccine within 28 day prior subunit vaccine within 14 day prior first dose Study Drug plan vaccination within 30 day follow last dose Study Drug . 10 . Pregnant nursing woman . 11 . History drug alcohol abuse , opinion Investigator , would interfere patient 's ability comply requirement study . 12 . Other active , uncontrolled comorbidities , opinion Investigator , would make subject unsuitable study unable comply study requirement . NOTE : Subjects take medication control underlie comorbidity may enrol change medication within 60 day prior first dose Study Drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>HSV</keyword>
	<keyword>Herpes</keyword>
	<keyword>genital infection</keyword>
	<keyword>vaccine</keyword>
</DOC>